Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

Researchers at the University of Toronto have identified hundreds of new proteins that could play a role in cystic fibrosis, and which may shed light on why some patients respond better than others to current therapies.

Pacific Biosciences reported after the close of the market on Tuesday that its fourth quarter 2021 revenues grew 33 percent year over year, while its full-year revenues jumped 65 percent.

On 12 February, the second meeting between the Mainland and Hong Kong on the COVID-19 outbreak as held in Shenzhen as the COVID-19 continued to spread in Hong Kong and confirmed cases continued to soar.

At the end of the reporting period, the total assets of Wantai Biopharmwere CNY 7.047 billion, an increase of 101.13% over the beginning of the period.

Olink reported before the opening of the market Monday that its Q4 revenues rose 61 percent.

A globally renowned expert in autoimmune diseases and systemic lupus erythematosus (SLE) at the University of Houston has identified potential biomarkers for neuropsychiatric symptoms of lupus.

The continuous outbreak of the 2021 epidemic has drawn attention to the issue of upstream raw materials in China's IVD industry.

Bruker on Friday reported that its fourth quarter revenues were up 9 percent year over year, driven by growth across almost all of the firm's business segments.

Along with the development of new therapies, advances in technologies that enable earlier diagnosis of cancer are critical to improve patient outcomes.

On January 30, China Telecom Medical Health Technology Co., Ltd. was established with a registered capital of CNY 200 million.